Contact tracing for tuberculosis and treatment for latent infection in a low incidence country

Swiss Medical Weekly

Volumn 138, Issue 5-6, 2008, Pages 78-84

  Lankensjold, Elisabeth ^a   Herrmann, François R ^b   Luong, B L ^b   Rochat, Thierry ^b   Janssen, Jean Paul ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Adherence; Contact tracing; Latent tuberculous infection; Tuberculosis

Indexed keywords

ISONIAZID; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; ASTHENIA; CONTACT EXAMINATION; CONTROLLED STUDY; DISEASE TRANSMISSION; DIZZINESS; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS; HUMAN; INCIDENCE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MENTAL DISEASE; PARESTHESIA; PATIENT COMPLIANCE; SIDE EFFECT; SKIN MANIFESTATION; THORAX RADIOGRAPHY; TINNITUS; TUBERCULIN TEST; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

EID: 39149089313     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Helbling P. La tuberculose en Suisse de 2001 à 2004 (Tuberculosis in Switzerland between 2001 and 2004). Bulletin de l'Office Fédé ral de la Santé Publique 2006;(22):428-33.
2. Rieder HL. Contacts of tuberculosis patients in high-incidence countries. Int J Tuberc Lung Dis. 2003;7(12 Suppl 3):S333-6.
3. Noertjojo K, Tam CM, Chan SL, Tan J, Chan-Yeung M. Contact examination for tuberculosis in Hong Kong is useful. Int J Tuberc Lung Dis. 2002;6:19-24.
4. Wang PD, Lin RS. Tuberculosis transmission in the family. J Infect. 2000;41:249-51.
5. Dasgupta K, Schwartzman K, Marchand R, Tennenbaum TN, Brassard P, Menzies D. Comparison of cost-effectiveness of tuberculosis screening of close contacts and foreign-born populations. Am J Respir Crit Care Med. 2000;162:2079-86.
6. Marks SM, Taylor Z, Qualls NL, Shrestha-Kuwahara RJ, Wilce MA, Nguyen CH. Outcomes of contact investigations of infectious tuberculosis patients. Am J Respir Crit Care Med. 2000;162:2033-8.
7. Bock NN, Metzger BS, Tapia JR, Blumberg HM. A tuberculin screening and isoniazid preventive therapy program in an inner-city population. Am J Respir Crit Care Med. 1999;159:295-300.
8. Davidow AL, Mangura BT, Wolman MS, Bur S, Reves R, Thompson V, et al. Workplace contact investigations in the United States. Int J Tuberc Lung Dis. 2003;7(12 Suppl 3):S446-52.
9. Underwood BR, White VL, Baker T, Law M, Moore-Gillon JC. Contact tracing and population screening for tuberculosis - who should be assessed? J Public Health Med. 2003;25:59-61.
10. Reichler MR, Reves R, Bur S, Thompson V, Mangura BT, Ford J, et al. Evaluation of investigations conducted to detect and prevent transmission of tuberculosis. JAMA. 2002;287:991-5.
11. Jereb J, Etkind SC, Joglar OT, Moore M, Taylor Z. Tuberculosis contact investigations: outcomes in selected areas of the United States, 1999. Im J Tuberc Lung Dis. 2003;7(12 Suppl 3):S384-90.
12. Sprinson JE, Flood J, Fan CS, Shaw TA, Pascopella L, Young JA, et al. Evaluation of tuberculosis contact investigations in California. Int J Tuberc Lung Dis. 2003;7(12 Suppl 3):S363-8.
13. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am Thoracic Soc. MMWR 2000;49(RR-6):1-51.
14. Driver CR, Balcewicz-Sablinska MK, Kim Z, Scholten J, Munsiff SS. Contact investigations in congregate settings, New York City. Int J Tuberc Lung Dis. 2003;7(12 Suppl 3):S432-8.
15. Lalvani A, Richeldi L, Kunst H. Interferon gamma assays for tuberculosis. Lancet Infect Dis. 2005;5:322-4.
16. Brändli O, Desgrandchamps D, Gabathuler U, Helbling P, Müller M, Nadal D, et al. Manuel de la tuberculose (Manual of tuberculosis). Bern: Ligue Pulmonaire Suisse (www.lung.ch); 2007.
17. Rieder H, Zellweger J, Quadri F, Desgrandchamps D. Dépistage et traitement de l'infection tuberculeuse, vaccination BCG (Detection and treatment of tuberculosis infection, BCG vaccination). Forum Med Suisse. 2003;23:531-9.
18. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax. 1998;53:536-48.
19. Swiss Association against Tuberculosis and Pulmonary diseases (ASTP). Lignes directrices pour la chimiothérapie préventive de la tuberculose (Guidelines for preventive therapy of tuberculosis). Bulletin de l'Office Fédéral de la Santé Publique 1991(Annex4):38-9.
20. Reichler M, Taylor Z, Castro KG. Factors in tuberculosis contact investigations. JAMA. 2002;287:2944.
21. Capewell S, Leitch AG. The value of contact procedures for tuberculosis in Edinburgh. Br J Dis Chest. 1984;78:317-29.
22. Behr MA, Hopewell PC, Paz EA, Kawamura LM, Schecter GF, Small PM. Predictive value of contact investigation for identifying recent transmission of Mycobacterium tuberculosis. Am J Respir Crit Care Med. 1998;158:465-9.
23. ATS/CDC joint statement. American Thoracic Society/Centers for Diseases Control and Prevention/Infectious Diseases Society of America: controlling tuberculosis in the United States. Am J Respir Crit Care Med. 2005;172:1169-227.
24. Shrestha-Kuwahara R, Wilce M, DeLuca N, Taylor Z. Factors associated with identifying tuberculosis contacts. Int J Tuberc Lung Dis. 2003;7(12 Suppl 3):S510-6.
25. Pfyffer G. Epidémiologie moléculaire de la tuberculose (Molecular epidemiology of tuberculosis). Bulletin de l'Office Fédéral de la Santé Publique 2002;9:175-6.
26. Philippin O. Role of DNA fingerprinting in epidemiological surveillance of tuberculosis in the Canton of Geneva (1995-7). Thesis No10190; Geneva University Hospital; 2001.
27. Horsburgh CR, Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med. 2004;350:2060-7.
28. Lalvani A, Pathan AA, Durkan H, Wilkinson KA, Whelan A, Deeks JJ, et al. Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet. 2001;357:2017-21.
29. Zellweger JP, Zellweger A, Ansermet S, de Senarclens B, Wrighton-Smith P. Contact tracing using a new T-cell-based test: better correlation with tuberculosis exposure than the tuberculin skin test. Int J Tuberc Lung Dis. 2005;9:1242-7.
30. Yun LW, Reves RR, Reichler MR, Bur S, Thompson V, Mangura B, et al. Outcomes of contact investigation among homeless persons with infectious tuberculosis. Int J Tuberc Lung Dis. 2003;7(12Suppl 3):S405-11.
31. Racine-Perreaud E, Zellweger JP. Preventive antituberculosis chemotherapy in 250 patients of the antituberculosis outpatient clinic in Lausanne. Schweiz Med Wochenschr. 1994;124:705-11.
32. Breuss E, Helbling P, Altpeter E, Zellweger JP. Screening and treatment for latent tuberculosis infection among asylum seekers entering Switzerland. Swiss Med Wkly. 2002;132:197-200.
33. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167:603-62.
34. Fountain FF, Tolley E, Chrisman CR, Self TH. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest. 2005;128:116-23.